Targeting G6PD (Glucose-6-Phosphate Dehydrogenase) as a Biomarker of Therapeutic Vulnerability in Renal Cell Carcinoma
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27062844 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Daniel Pinheiro Ferreira und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinics Hospital, Universidade Federal do Triângulo Mineiro, Uberaba 38025-180, Brazil. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Glucosephosphate Dehydrogenase, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa do Estado de Minas Gerais, Centro de Pesquisa em Rim - CePRim, UFTM (CePRim), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq).
Abstract (Originalsprache)
Renal cell carcinoma (RCC) is the most common kidney cancer, with increasing global incidence. Despite advances with VEGF-targeted tyrosine kinase inhibitors (TKIs) and immunotherapies, therapeutic resistance remains frequent, limiting long-term benefits. This highlights the need for potential biomarkers of tumor aggressiveness and therapeutic candidates, such as glucose-6-phosphate dehydrogenase (G6PD), whose altered expression has been associated with several cancers. We evaluated G6PD gene and protein expression in 121 RCC samples through immunohistochemistry and assessed functional role in vitro approaches. 786-O and ACHN cells were treated with the inhibitor G6PDi-1 and the anti-VEGF cabozantinib/lenvatinib. G6PD mRNA levels were higher in tumors than in non-neoplastic tissues, indicating shorter overall survival in clear cell (ccRCC) and papillary (pRCC) subtypes. Immunolabeling confirmed a higher expression in pRCC and associations with pathological features. CRISPR and RNAi datasets revealed a stronger G6PD dependency in the ccRCC. A high gene expression was observed in lenvatinib non-responder cell lines, and DepMap dose–response curves indicated modest responses to VEGF inhibitors. In vitro, ACHN was more sensitive to VEGF inhibition, particularly cabozantinib, whereas G6PDi-1 had stronger effects in 786-O, impairing viability, migration, and clonogenic capacity. Our findings support G6PD as a biomarker of tumor aggressiveness and G6PDi-1 as a potential therapeutic in RCC models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinics Hospital, Universidade Federal do Triângulo Mineiro, Uberaba 38025-180, Brazil.
- Department of Pathology, Genetics and Evolution, Universidade Federal do Triângulo Mineiro, Uberaba 38025-015, Brazil.
- Kidney Research Center, Universidade Federal do Triângulo Mineiro, Uberaba 38025-015, Brazil.
- Department of Clinical Surgery, Universidade Federal do Triângulo Mineiro, Uberaba 38025-440, Brazil.
ORCID-Profile: Ana Carolina Souza Mizael, Julia Victória Bonifácio Cabrieira, Crislaine Aparecida Silva, Régia Caroline Peixoto Lira
Förderung
- Fundação de Amparo à Pesquisa do Estado de Minas Gerais
- Centro de Pesquisa em Rim - CePRim, UFTM (CePRim)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
- Centro de Pesquisa em Rim–CePRim, UFTM
Zitieren
APA
Ferreira, D. P., Mizael, A. C. S., Cabrieira, J. V. B., Silva, R. V. N., Araújo, L. S., Silva, C. A., Ribeiro, K. B., Michelleti, A. M. R., Machado, J. R., & Lira, R. C. P. (2026). Targeting G6PD (Glucose-6-Phosphate Dehydrogenase) as a Biomarker of Therapeutic Vulnerability in Renal Cell Carcinoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27062844
Vancouver
Ferreira DP, Mizael ACS, Cabrieira JVB, Silva RVN, Araújo LS, Silva CA, et al. Targeting G6PD (Glucose-6-Phosphate Dehydrogenase) as a Biomarker of Therapeutic Vulnerability in Renal Cell Carcinoma. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27062844
BibTeX
@article{Ferreira2026,
author = {Ferreira, Daniel Pinheiro and Mizael, Ana Carolina Souza and Cabrieira, Julia Victória Bonifácio and Silva, Rafaela Viviane Neves and Araújo, Liliane Silvano and Silva, Crislaine Aparecida and Ribeiro, Karen Bento and Michelleti, Adilha Misson Rua and Machado, Juliana Reis and Lira, Régia Caroline Peixoto},
title = {Targeting G6PD (Glucose-6-Phosphate Dehydrogenase) as a Biomarker of Therapeutic Vulnerability in Renal Cell Carcinoma},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27062844}
}
EUVIMED